Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships  with cognitive behavioral therapy rehab programs suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry at

The extensive range includes drugs such as but not limited to:

  • Bladder Cancer Drugs

  • Bone Cancer Drugs

  • Breast Cancer Drugs

  • Leukemia Drugs

  • Liver Cancer Drugs

  • Lung Cancer Drugs

  • Prostate Cancer Drugs

  • Rhabdomyosarcoma Drugs

  • Skin Cancer Drugs

  • Soft Tissue Sarcoma Drugs

  • Thyroid Cancer Drugs

  • Non Small Cell Cancer Drugs

  • Newly approved FDA / EMA Drugs